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Abstract
Background: Systemic mastocytosis is a rare myeloproliferative disease characterized by the uncontrolled
proliferation of aberrant mast cells. It has varying clinical manifestations. For unknown reasons, pulmonary
localization of mastocytosis is extremely rare.
Case presentation: In this report, we describe a case of a young Caucasian female with systemic mastocytosis who
had an associated hematological non-mast-cell lineage disease with pulmonary interstitial disease directly related to
her mastocytosis. The diagnosis was proven by the presence of mast cells in bronchoalveolar lavage. The treatment
of her associated hematological disease (myelofibrosis with myelodysplasia) was hampered by rapidly declining
pulmonary function and progressive organ dysfunction due to aggressive systemic mastocytosis. She died
approximately 1 year after the diagnosis.
Conclusions: To our knowledge, this is the first case in which mast cells were detected in bronchoalveolar lavage.
Moreover, to date, only two other cases of pulmonary interstitial disease due to mastocytosis have been published.
Juggling therapies for systemic mastocytosis and myelofibrosis is very difficult; however, aggressive therapy for both
diseases is essential to give these patients a chance to survive.
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Background
Systemic mastocytosis (SM) is a myeloproliferative
disease characterized by uncontrolled proliferation of
aberrant mast cells. According to the World Health
Organization criteria, different subtypes with different
clinical phenotypes and prognoses are identified [1].
When SM coincides with an associated hematological
non-mast-cell lineage disease, mostly of myeloid origin, it
is called SM-AHNMD. To date, there are few effective
treatment options for advanced SM. In most patients
with SM-AHNMD, only the associated hematological
disease is treated. However, conventional myeloablative
chemotherapy is not effective in reducing mast cell
numbers. This can cause a difficult dilemma of Scylla and
Charybdis when SM-AHNMD coincides with aggressive
SM causing organ dysfunction.
Case presentation
The patient, a 26-year-old Caucasian woman, presented
to our hematology department after a routine laboratory
investigation revealed normocytic anemia with increased
myeloid precursor cells, including 5 % blasts. At that
time, the patient had no other clinical symptoms aside
from a persisting open wound on her lower leg, which
was the reason for conducting the first laboratory tests.
A bone marrow examination was performed to identify
the cause of her anemia. Aspiration of bone marrow was
invariably impossible throughout the treatment because
of severe myelofibrosis. Therefore, only bone marrow
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core biopsies were available, which showed a highly
hypercellular marrow with an excess of myeloid precursor
cells (5 % CD34+ and 17 % CD117+). There were signs of
dysplasia in all cell lines. Furthermore, increased reticulin
was seen corresponding to myelofibrosis grade 3. Molecu-
lar testing revealed a 47,XX+8 karyogram with a weakly
detectable JAK2 V617F mutation. A diagnosis of myelo-
proliferative neoplasia (MPN) with aspects of myelodys-
plastic syndrome (MDS) was made. On the basis of a high
Cervantes score [2], an up-front hematopoietic stem cell
transplant (HSCT) was planned, but then postponed be-
cause of liver enzyme abnormalities. Analysis revealed only
hepatosplenomegaly that was considered secondary to
extramedullary hematopoiesis at that time.
Six months later, a follow-up bone marrow exami-
nation showed an unexpected finding: Approximately
25 % of the marrow was occupied with clusters of
spindle-shaped mast cells (Fig. 1). Immunophenotyping
was not feasible, because bone marrow aspiration was
unsuccessful; however, the c-KIT D816V mutation was
detectable, and the patient’s serum tryptase level was
elevated (194 μg/L). Thus, the diagnosis was shifted to
SM-AHNMD. Simultaneously, the patient developed
dyspnea, coughing, fatigue, and diffuse abdominal pain.
Like most patients with aggressive SM, she had no mast
cell mediator-related symptoms such as pruritus, flush-
ing, or diarrhea. The symptoms had an insidious onset
and were gradually progressive with additional fever and
weight loss, eventually necessitating admission to the
hematology ward. She initially had no hypoxemia. Subse-
quently, computed tomography (CT) of the chest showed
a diffuse reticular aspect with areas of ground-glass ap-
pearance and widening of interlobular septa (Fig. 2). The
patient had mild restriction with a total lung capacity
(TLC) of 3.76 L (77 % of predicted), a forced vital capacity
(FVC) of 2.97 L (81 % of predicted), and an impaired dif-
fusing capacity of the lung for carbon monoxide (DLCO)
of 62 % of predicted with a corrected diffusion capacity
for alveolar volume (TL/VA) of 86 %. Bronchoalveolar
lavage (BAL) of the right upper and middle lobes was per-
formed to rule out infectious diseases, mainly Pneumocys-
tis jirovecii. Again unexpectedly, mast cells were identified
by morphological examination of BAL fluid. Furthermore,
neutrophilic and eosinophilic granulocytes, small lympho-
cytes, and alveolar macrophages were seen. Subsequent
immunophenotyping revealed that 8 % of the cells had a
phenotype matching neoplastic mast cells (CD117+/CD34−/
HLA-DR−/CD2−/CD25+). No other monoclonal cell popu-
lation was found. Immunophenotyping of peripheral
blood showed that merely 0.3 % had a mast cell pheno-
type, ruling out contamination of the BAL by blood. A
lung biopsy was denied by the patient, but the BAL was
considered enough evidence for the interstitial pulmonary
disease being directly related to mastocytosis.
The patient had SM-AHNMD with pulmonary involve-
ment, hepatosplenomegaly, skeletal lesions, and lymph-
adenopathy, with associated MPN/MDS. Concurrent with
the aforementioned clinical admission because of worsen-
ing pulmonary symptoms, it was noted that the peripheral
myeloblasts had increased to 19 %, warranting myeloabla-
tive chemotherapy. The Eastern Cooperative Oncology
Group status of the patient was 2 at that time. She was
treated with high-dose cytarabine and idarubicin in cycle
1, and high-dose cytarabine combined with amsacrine in
cycle 2. Complete remission of the MDS was achieved
after cycle 2, with no blasts identifiable in a follow-up
bone marrow examination. On the basis of knowing that
conventional myeloablative chemotherapy is not effective
for SM, prednisolone 1 mg/kg was added from the start of
the first remission induction cycle. This resulted in short
improvement of the pulmonary symptoms and a decrease
of the serum tryptase level to 46.8 μg/L. However, re-
peated CT scans showed progressive disease, which was
reflected by pulmonary function testing, with a FVC of
2.36 L (65 %), a forced expiratory volume in 1 second of
1.92 L (61 %), and a DLCO of 58 % of predicted. More-
over, tapering of corticosteroids from 60 to 40 mg/day
resulted in quick recurrence of pulmonary symptoms.
Therefore, dasatinib was started, but this caused unaccep-
table side effects (headache and anorexia). Moreover, a rise
in blast count was seen 2 months after achievement of
complete remission, with a blast count of 20 % in bone
Fig. 1 Bone marrow histopathology. a A hematoxylin and eosin stain
of the second bone marrow core biopsy showed a highly hypercellular
marrow with multiple spindle-shaped mast cells (example within the
white oval). b Gömöri stain reveals extensive reticulin fibers, correlating
with myelofibrosis grade 3. c Tryptase stain shows diffuse infiltration of
mast cells. (Published with consent from the Pathology Department of
Erasmus MC, Rotterdam.)
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marrow. Intensive myeloablative chemotherapy was not
considered feasible at that time, owing to the patient’s
pulmonary disease with a TLC of 2.86 L (58 %), an FVC of
1.78 L (49 %), a DLCO of 26 %, and a TL/VA of 52 %. In a
last effort, cladribine was given to palliatively treat the
patient’s mastocytosis. Unfortunately, shortly after the first
cycle of cladribine, the patient died as a result of severe
neutropenic sepsis with mucositis. Her death occurred
5 months after the discovery of both the presence of SM
and the pulmonary interstitial disease.
Discussion
Here, We describe the extraordinary history of a young
woman who died as a result of a very rare complication of
SM-AHNMD. To our knowledge, only two cases of inter-
stitial lung disease due to SM have been reported [3, 4].
Furthermore, our case is the first in which mast cells were
identified in the BAL. In 2000, Schmidt et al. reported a
case of a 54-year-old man with indolent SM who devel-
oped mild reticular infiltration of both lungs with infiltra-
tion of mast cells evidenced by lung biopsy. Their patient’s
pulmonary status improved after 6 months of treatment
with interferon-α2A [4]. Furthermore, Kelly et al. described
a case of a 70-year-old woman with SM-AHNMD who
developed increasing dyspnea with a markedly impaired
diffusion capacity and a fine reticular interstitial pattern
visualized by chest CT. Lung biopsy showed increased
mast cells with septal fibrosis [3]. Unfortunately, no details
on treatment or follow-up were given for their case.
Despite the fact that mast cells are abundant in the
lungs, pulmonary manifestations of SM are rare.
Moreover, when pulmonary involvement is present, it
often consists of asthma-like bronchial hyperreactivity
or intrapulmonary nodules [5, 6]. We can only speculate
on the pathogenesis of interstitial pulmonary disease due
to SM. The phenotypical differences in pulmonary versus
skin mast cells might provide a (partial) explanation for
the rarity of actual pulmonary infiltration by mast cells
[7]. Moreover, interstitial fibrosis might contribute to the
development of interstitial lesions. It is currently widely
accepted that mast cells are important players in the field
of fibrosis by both activation of fibroblasts by histamine
and direct transforming growth factor-β production [8, 9].
This theory is supported by a case reported by Kelly et al.,
who found fibrosis in a lung biopsy [3]. However, this still
does not explain why so few patients with SM develop
pulmonary interstitial disease.
In our patient, the diagnosis of SM was probably
missed in the first bone marrow biopsy. When clinical
suspicion is lacking, aberrant mast cells can be missed
Fig. 2 Computed tomographic images obtained at diagnosis (a-c) and after 4 months (d-f). a and b The first computed tomograms of the chest
show a ground-glass aspect that is most pronounced in the apical areas with a diffuse reticular aspect and widening of interlobular septa. At this
time, the groundglass was mainly localized around bronchovascular bundles. c and f The skeleton shows multiple focal sclerotic lesions. d and e
Computed tomographic scans obtained 4 months after the first ones show progressive and diffuse reticular ground-glass lesions
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easily, especially in such hypercellular marrow (Fig. 1)
[10]. Next, when the patient developed interstitial lung
lesions, again an accidental finding of mast cells in the
BAL with morphological examination gave away the
diagnosis of mastocytosis-related pulmonary interstitial
disease. This would have been missed without morpho-
logical examination. A high index of suspicion is there-
fore needed to diagnose pulmonary mastocytosis.
The combination of these two aspects of SM-AHNMD
leads to a difficult dilemma of Scylla and Charybdis, as
there are currently no cytoreductive therapies that can
treat both MDS with excessive blast count and SM. In
our case, fear for toxicity of combining two types of
cytoreductive treatments probably led to undertreatment
of the patient’s mastocytosis. The patient then went into
a downward spiral in which the pulmonary lesions
hampered any further intensive treatment. One could
wonder whether the patient’s mastocytosis should have
been treated more aggressively from the moment it was
diagnosed, even postponing the treatment of the MPN/
MDS. In 2009, Ustun et al. reported a case of an adult
patient with aggressive SM with acute myeloid leukemia
(AML) in whom dasatinib was added in an early phase
of myeloablative therapy, which resulted in long-term
remission of both the AML and the mastocytosis [11].
When feasible, HSCT can also induce long-term remis-
sion of advanced SM, and up-front HSCT is probably
the treatment of choice [12].
Conclusions
This report describes a very rare case of interstitial lung
disease due to aggressive SM in a patient with SM-
AHNMD. It is important that awareness is increased for
this rare but lethal complication of aggressive SM.
Immunophenotyping of BAL cells can serve as an alter-
native and less invasive method of obtaining a diagnosis
in cases where a lung biopsy is not feasible. Timely and
aggressive cytoreductive treatment of both the SM and
the associated hematological disease is of paramount im-
portance with regard to the survival of these patients.
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